Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine

EMERYVILLE, Calif., Feb. 3 NeurobiologicalTechnologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received aquarterly royalty payment of approximately $1.5 million from MerzPharmaceuticals GmbH (Merz) for sales of Memantine for the treatment ofAlzheimer's disease. Under an exclusive marketing agreement, NTI currentlyreceives quarterly royalty payments on certain sales of Memantine by Merz andits marketing partners.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company focusedon developing novel, first-in-class agents for central nervous systemconditions and other serious unmet medical needs. The company recentlyterminated development of its most advanced product candidate, Viprinex(TM)(ancrod), which was studied in Phase 3 clinical trials for evaluation as a newdrug to treat acute ischemic stroke. NTI has an early-stage developmentprogram for Alzheimer's disease and rights to receive payments on an approveddrug for Alzheimer's disease and an investigational drug which has recentlycompleted a Phase 3 trial for brain swelling.

SOURCE Neurobiological Technologies, Inc.

Latest Press Release on General News

Single-Cell Multi-Omics Analysis of IASO Bio's Equecabtagene Autoleucel in the Treatment of Autoimmune Diseases of the Central Nervous System Published in Science Immunology

SHANGHAI , NANJING , China , and SAN JOSE, Calif. , May 10, 2024 /PRNewswire/ -- On May 10, 2024 , the impactful international academic journal, Science Immunology , a sub-j...

Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis

The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers usi...

Philips Shareholders Approve all Proposals at the AGM 2024

May 7, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that its shareholders approved all proposals at the Annual General Meeting of Shar...

Brains Bioceutical Announces the Addition of Industry Veteran John Boshart to its Animal Health Division

VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Today marks a pivotal development for Brains Bioceutical Corp ("Brains Bio"), as it significantly strengthens its Veterin...

Nicklaus Children's Health System, Philips to Provide Innovative Patient and Staff Experience, Helping to Enhance Outcomes for the Smallest of Patients

April 30, 2024 Philips AI-enabled diagnostic and experiential technologies help put patients at ease while empowering staff with faster, high-quality scans and increased diagnostic c...